Table 3.
Patients’ charactristics at baseline (after propensity score macthing).
| Parameter | SM group (N = 191) | RM group (N = 191) | Total (N = 382) | Difference (test)a |
|---|---|---|---|---|
| Age, years, mean (SD) | 65.13 (12.85) | 64.77 (13.16) | 64.95 (12.99) | p = 0.7862 |
| Male gender, % | 82.72% (158/191) | 78.01% (149/191) | 80.37% (307/382) | p = 0.246 |
| Diabetes, % | 18.85% (36/191) | 21.99% (42/191) | 20.42% (78/382) | p = 0.446 |
| Pulmonary arterial hypertension, % | 59.16% (113/191) | 58.64% (112/191) | 58.90% (225/382) | p = 0.917 |
| Severe chronic kidney disease, % | 2.62% (5/191) | 3.66% (7/191) | 3.14% (12/382) | p = 0.557 |
| Secondary cardiovascular prevention, % | 39.79% (76/191) | 34.55% (66/191) | 37.17% (142/382) | p = 0.290 |
| Stroke or TIA, % | 8.38% (16/191) | 7.85% (15/191) | 8.12% (31/382) | p = 0.851 |
| Myocardial infarction, % | 31.94% (61/191) | 33.51% (64/191) | 32.72% (125/382) | p = 0.744 |
| Coronary disease, without MI, % | 16.75% (32/191) | 12.57% (24/191) | 14.66% (56/382) | p = 0.247 |
| Thromboembolism or vasculopathy, % | 3.14% (6/191) | 5.76% (11/191) | 4.45% (17/382) | p = 0.215 |
| Deep vein thrombosis, % | 65.45% (125/191) | 70.16% (134/191) | 67.80% (259/382) | p = 0.324 |
| Aortic stenosis, % | (3/191) | 2.09% (4/191) | 1.83% (7/382) | p = 0.703 |
| Atrial fibrillation, % | 30.37% (58/191) | 26.70% (51/191) | 28.53% (109/382) | p = 0.428 |
| Treatment with ACE inhibitors/ARBs, % | 83.60% (158/189) | 80.42% (152/189) | 82.01% (310/378) | p = 0.422 |
| Treatment with beta-blockers, % | 94.18% (178/189) | 94.15% (177/188) | 94.16% (355/377) | p = 0.990 |
| Treatment with diuretics, % | 86.24% (163/189) | 78.31% (148/189) | 82.28% (311/378) | p = 0.043 |
| Treatment with anticoagulation drugs, % | 30.89% (59/191) | 37.57% (71/189) | 34.21% (130/180) | p = 0.170 |
| Treatment with antiarrhythmic drugs, % | 16.67% (30/180) | 20.21% (38/188) | 18.48% (68/368) | p = 0.381 |
| Treatment with ICD, % | 62.83% (120/191) | 63.87% (122/191) | 63.35% (242/382) | p = 0.832 |
| Treatment with CRT-D, % | 37.17% (71/191) | 36.13% (69/191) | 36.65% (140/382) | |
| CHA2DS2-VASc score, mean (SD) | 2.76 (1.66) | 2.87 (1.65) | 2.82 (1.66) | p = 0.5171 |
| Left ventricular ejection score, % | ||||
| <35% | 12.57% (24/191) | 16.23% (31/191) | 14.40% (55/382) | p = 0.172 |
| 35%–44% | 14.14% (27/191) | 7.85% (15/191) | 10.99% (42/382) | |
| 45%–54% | 13.61% (26/191) | 11.52% (22/191) | 12.57% (48/382) | |
| >55%; | 59.69% (114/191) | 64.40% (123/191) | 62.04% (237/382) | |
| NYHA Functional Classification, % | ||||
| Class I | 18.85% (36/191) | 19.9% (38/191) | 19.37% (73/382) | p = 0.400 |
| Class II | 74.35% (142/191) | 69.63% (133/191) | 71.99% (275/382) | |
| Class III | 6.81% (13/191) | 10.47% (20/191) | 8.64% (33/382) | |
| Class IV | 0.00% (0/191) | 0.00% (07191) | 0.00% (0/382) | |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CHA2DS2-VASc score, Congestive heart failure, Hypertension, Age over 75 years, Diabetes mellitus, Stroke, Vascular disease, Age between 65 and 74 years, Sex Category (female); CRT-D, cardiac resynchronization therapy defibrillators; ICD, implantable cardioverter-defibrillators; NYHA, New York Heart Association; RM, remote monitoring; SD, standard deviation; SM, standard monitoring; TIA, transient ischemic attack.
a
t-test for age and CHADS score; chi-square test for all other variables. Statistically significant differences between groups are marked in bold.